Showing results (81-90 of 225) with videos related to

Sort By:
Pageof 23
Biomedicines|July 29, 2023
The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth In Vitro and In VivoYuta Mitobe, Shuhei Suzuki, Yurika Nakagawa-Saito, et al.
International Journal of Molecular Sciences|July 28, 2022
HDAC Class I Inhibitor Domatinostat Preferentially Targets Glioma Stem Cells over Their Differentiated ProgenyYurika Nakagawa-Saito, Shinichi Saitoh, Yuta Mitobe, et al.
Cancers|September 9, 2023
Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor CellsYuta Mitobe, Shuhei Suzuki, Yurika Nakagawa-Saito, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 26, 2016
[Study of the Identification Rate of Sentinel Lymph Node Biopsy after Partial Breast Resection]Shuhei Suzuki, Kenichi Sakurai, Keita Adachi, et al.
Anticancer Research|January 1, 2015
Differential contribution of ROS to resveratrol-induced cell death and loss of self-renewal capacity of ovarian cancer stem cellsManabu Seino, Masashi Okada, Keita Shibuya, et al.
Biomedicines|August 9, 2020
Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug RepurposingShuhei Suzuki, Masahiro Yamamoto, Tomomi Sanomachi, et al.
Current Issues in Molecular Biology|July 23, 2025
Potential Resistance to Oxaliplatin-Based Regimens in Gastric Cancer Patients with ERBB2 R678Q Mutation: Evidence from a National Genomic DatabaseShuhei Suzuki, Manabu Seino, Hidenori Sato, et al.
Oncotarget|December 8, 2017
Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson's disease, as an anti-cancer stem cell drugMasashi Okada, Hiroyuki Takeda, Hirotsugu Sakaki, et al.
Neuro-Oncology Advances|November 12, 2021
Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclaxMasahiro Yamamoto, Tomomi Sanomachi, Shuhei Suzuki, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 8, 2014
[Indoleamine 2, 3-dioxygenase activity for breast cancer patients with recurrence 5 or more years after surgery]Kenichi Sakurai, Shigeru Fujisaki, Saki Nagashima, et al.
Pageof 23